Indexes might not be in correction territory, but they're getting closer. Now's the time to consider what moves to make.
VIDEO ON MSN MONEY
The case of the missing 4s has been solved.
By Selena Maranjian
Something strange happened last month, when Apple (AAPL) reported its quarterly earnings: They fell short of Wall Street's expectations. That has rarely happened in recent years, and the stock sank on the news, down about 7% initially. The episode was a good reminder that many companies have set us up to expect them to beat expectations -- and that bad things can happen when they don't.
The technology realm includes many frequent exceeders. For example:
Betting against the stock was finally allowed to begin this week, and traders have jumped in with enthusiasm.
There is strong demand to borrow the stock and bet against it, Bloomberg reports. Shorts like to sell borrowed stock, expecting to profit by buying the shares back when the price drops.
Barnes & Noble will be one of the sector's top performers, one analyst says.
By Jeannine Poggi, TheStreet
Barnes & Noble (BKS) could double its stock price by 2013, according to an analyst.
"We believe as the market understands and appreciates the digital opportunity for the company and the sustainability of EBITDA at the store level, at least in the next few years the stock will prove to be one of the top performing retail/tech names in the market," Janney Capital Markets analyst David Strasser wrote in a note.
Numerologists say Nov. 11 is a lucky day. If that's the case, these 11 companies just might do the trick for investors.
By Frank Byrt, TheStreet
Numerologists say Friday is a lucky day, given the "11/11/11" date. Superstitious investors who have come to believe that traditional fundamental analysis methods are haywire in the seesawing marketplace may want to consider promising stocks with beaten-down prices of under $11.
Small-cap stocks, which typically include those trading for less than $11, are down 5.2% this year, compared with the large-cap bellwether S&P 500 ($INX) 0.6% decline. But the small-cappers show signs of having bottomed, as they are up 9.7% in the past month and 5.4% over 13 weeks, according to Morningstar.
These stocks show favorable chart patterns and are close to staging upside breakouts.
By Tom Aspray, MoneyShow.com
Stocks have had a fairly choppy week, which makes the weekly close more important. A higher weekly close will be a positive sign, and the very strong action in crude oil on Thursday is a bullish signal for stocks.
As discussed previously, crude oil futures often break up or down ahead of the stock market. Wednesday's heavy selling in stocks increased the possibility of a deeper stock market correction, and while crude oil was also lower, it made new rally highs on Thursday.
With the introduction of its lightest roast ever in January, the company is attempting to reach a broader range of coffee drinkers.
Based on its consumer research, Starbucks is offering its Blonde line for the estimated 40% of American coffee drinkers, or 54 million people, who prefer a lighter roast. The new coffees in the Blonde category include several under the Veranda and Willow blend names.
Starbucks' competitors in the specialty-coffee market include McDonald's (MCD), Caribou Coffee (CBOU) and Peet's Coffee (PEET).
The advancement of tablets and smartphones has made Internet and mobile sales a prime strategy for many companies.
The teen apparel sector, including companies like Aeropostale (ARO), Abercombie & Fitch (ANF), American Eagle Outfitters (AEO) and Gap (GPS), is abuzz with these technical advancements in retail, with the 15-25 age group at the core of key smartphone and tablet users.
This biotechnology stock has the brightest growth prospects in Standard &Poor's large-cap biotech universe.
By Steven Silver, Standard & Poor's The Outlook
S&P Capital IQ considers Celgene (CELG) one of the biotechnology stocks best positioned for long-term growth, with solid core product growth, an advancing new product pipeline, and a strong financial position.
We expect Celgene to deliver earnings growth at a compound annual rate of 21% from 2010 through 2013, driven by expanding sales of its key cancer drug Revlimid. This figure represents the brightest growth prospects we see in the large-cap biotech industry.
We also believe that the positive resolution to a European review of the drug’s safety will further improve investor sentiment on the shares.
Celgene develops and markets pharmaceuticals to treat cancer, immunological, and inflammatory disorders.
The movement is facing winter, an increasingly crowded news environment and an inability to directly affect the high-paid CEOs and bankers it's targeting.
By Peter Leeds, guest columnist
The faster anything rises, generally the faster it falls. Occupy Wall Street may be another example of this, as media coverage, social media activity, and activist numbers have all started dropping off. This is only expected to continue, especially with the onset of winter.
According to Google Trends, searches for Occupy Wall Street have fallen by 66% from their October 15th peak to November 11th. This is reinforced further by the Pew Research Center's weekly news index, which shows "Occupy Wall Street" dropping from 10% of total news coverage across their network on October 1st, to where it sits currently at less than 4%.
Disney stock pops on quarterly earnings report.
By Peter Cohan, InvestorPlace
In an economy that's hardly booming, people quickly defer to TV as a cheap entertainment option. But with a glut of options, any entertainment company worth its airwaves has to produce compelling content to snag a big share of those viewers.
Disney Co. (DIS) is one entertainment company that must be hitting that mark, given its blowout earnings report Thursday.
Famed contrarian David Dreman holds 1.4 million shares of this high-yielding healthcare REIT.
I’ve wanted to add a real estate investment trust to our Perpetual Income Portfolio for a while now. Boy, am I glad I waited.
After a recent pounding, many REITs now have very attractive yields. Perhaps none more so than Omega Healthcare Investors (OHI), which leases facilities to nursing home operators. The REIT now yields a mouthwatering 9%.
BUD, TAP on the losing end of volume sales
By Peter Cohan, InvestorPlace Writer
Do people drink less beer during periods of slow economic growth so they can save money, or do they drink more to drown their sorrows? The great thing about this question is that there are two publicly traded companies -- Anheuser-Busch InBev (BUD) and Molson Coors Brewing Company (TAP) -- whose earnings we can analyze to gain insight into this question.
And here's another: Should you invest in either company?
Not long ago, there was one stock you could buy into every dip without fear. Not anymore.
Sometimes you don't get to write everything or say everything you want on TV, but I wanted to give you my entire piece on Apple (AAPL) that some people said was at the heart of the decline Thursday.
I had to do a truncated No Huddle version because of the exigencies of the moment. I also want to point out that an outfit called Cleveland Research is cutting Apple numbers for precisely what one of the worry points is: the surfeit of tablets. It's a worrisome development, given how the iPad has trounced all other comers.
The online broker decides not to sell itself. The media giant reports better-than-expected earnings.
By Andrea Tse, TheStreet
Updated at 9:15 a.m. ET
E-Trade Financial (ETFC) has decided not to sell itself after a three-month strategic review. Rejecting pressure from shareholder Citadel to sell to another online broker such as TD Ameritrade (AMTD) or Charles Schwab (SCHW), E-Trade CEO Steven Freiberg said, "The management team will continue to execute on our strategy designed to create value for both our stockholders and our customers."
Walt Disney (DIS) reported fiscal-fourth-quarter earnings and revenue that beat analysts' estimates, thanks to strong sales at its media networks and resorts. Excluding charges related to restructuring and impairment, Disney earned 59 cents, beating the 54-cent forecast of analysts surveyed by Thomson Reuters. Revenue rose 7% to $10.43 billion, topping expectations for $10.36 billion.
Yields on French government bonds aren't close to those of Italy, but they are moving in the wrong direction.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The company is scrambling to protect its equities arm, which could face declining volume and revenue as competitors close the gap.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The stock market finished the Wednesday session on an upbeat note with the Nasdaq (+1.3%) ending in the lead. The S&P 500 settled higher by 1.1% with all ten sectors posting gains.
The benchmark index spent the entire trading day in the green, rallying to new highs during the last hour of action. The tech-heavy Nasdaq, meanwhile, briefly dipped into the red during morning action, but was able to recover swiftly.
Stocks began the trading day with modest gains ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|